Twist Bioscience Director Chess Executes Strategic Buy‑Sell Play: $11.89 Discount Sale Followed by $47.00 Premium Purchase Highlights Confidence in Synthetic DNA Future.

Insider Activity Highlights a Shift in Twist Bioscience’s Ownership Structure

The latest Rule 4 filing from Twist Bioscience Corp. shows that director Robert Chess, a trustee of the Chess 1997 Trust, sold 10 000 shares of the company’s common stock on March 17, 2026. The sale was executed under a Rule 10b‑5‑1 trading plan that Chess had adopted on December 10, 2025, and it was priced at $11.89 per share—well below the market price of $44.86 at the time. This indicates that Chess was exercising a pre‑planned, lock‑box sale rather than responding to an acute market signal.

At the same time, Chess used the plan to buy 10 000 shares at $47.00, the same day, adding a substantial position at a price roughly 5.5 % above the day’s close. The net effect is a modest increase in his post‑transaction ownership from 21,084 to 31,084 shares, reflecting a cautious but still bullish stance on the company’s prospects.

What It Means for Investors

For the market, these concurrent buy and sell transactions suggest that Chess is balancing liquidity needs with a long‑term view. The $11.89 sale price is a significant discount, implying that the director is comfortable accepting lower liquidity in exchange for a larger shareholdings at a higher purchase price. The overall pattern—small, frequent trades under a 10b‑5‑1 plan—reduces the risk of market impact and signals disciplined capital allocation. Investors may interpret this as a vote of confidence: Chess is willing to commit capital even when the price is higher, while still maintaining flexibility to liquidate at a discount.

Moreover, the transaction aligns with a broader trend among Twist insiders. In March, several executives (e.g., CFO Laponis, COO Finn John) executed sizable sales, often around the $46–$48 range, while a handful of directors continued to buy shares. This mix suggests that while some insiders may be cash‑constrained or seeking to diversify, others view the company’s trajectory—particularly in synthetic DNA and genome engineering—as a long‑term play.

Chess’s Historical Trading Pattern

Reviewing Chess’s past filings shows a consistent use of 10b‑5‑1 trading plans and a pattern of selling at discounts to market and buying at a premium. In February, Chess sold 2,184 shares at $48.26 and later bought 5,095 shares at $0.00 (reflecting exercise of options) and again purchased 5,095 shares at $0.00, maintaining a holding of 42,528 shares. The current transaction reflects a similar strategy: a large discount sale followed by a premium purchase, ultimately netting a slightly larger stake.

This disciplined approach is common among seasoned directors who wish to mitigate concentration risk while preserving downside protection. Chess’s trades have not deviated from the company’s average volatility; his holdings remain well within the thresholds set by the SEC for “independent directors” under Section 16(b) compliance.

Future Outlook for Twist

With a market cap of $2.8 billion and a negative price‑earnings ratio of –34.9, Twist’s stock is trading at a deep discount relative to earnings, suggesting significant upside if the company can monetize its synthetic biology platform. Recent insider activity—particularly the mix of buys and sells—indicates that executives believe the company’s valuation will improve in the near term, especially as the company ramps up its genome‑engineering pipeline.

For investors, the key signals are: (1) insiders are willing to lock in positions at a range of prices, implying confidence; (2) the company is executing a disciplined trading plan that limits market impact; and (3) the broader insider trend of selling at roughly $46–$48 may reflect a need for liquidity, but the continued buying suggests a belief in the company’s long‑term strategy. These factors together point to a cautiously optimistic outlook, with insiders backing the company’s prospects while managing personal exposure.